The SNRPN Bipartite Imprinting Centre in Region 15q11–q13 and Its Epigenetic Role in the Pursuit of a Cure for Angelman Syndrome
While no disease-modifying therapy is yet approved, the convergence of detailed mechanistic understanding of the SNRPN bipartite imprinting centre with scalable epigenetic editing technologies represents the most plausible route towards a transformative, rather than purely symptomatic, treatment for Angelman syndrome,...